Multicenter Retrospective Study of LCIG Therapy in Japan: Efficacy, Factors Associated with Discontinuation, and Case-based Insights.
Multicenter Retrospective Study of LCIG Therapy in Japan: Efficacy, Factors Associated with Discontinuation, and Case-based Insights.
Where did the research take place?
Possible study sites were matched from the text; these need review.
JP · Possible study site · country only
Methods We retrospectively collected clinical data from PwPD who received LCIG across nine institutions in Kyushu, Japan.Location evidence
Fukuoka, JP · Author affiliation
Department of Neurology, Fukuoka University School of Medicine, Japan.Location evidence
JP · Author affiliation · country only
Department of Neurology, Takagi Hospital, Japan.Location evidence
Kagoshima, JP · Author affiliation
Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Japan.Location evidence
Okinawa, JP · Author affiliation
Division of Neurology, National Okinawa Hospital, National Hospital Organization, Japan.Location evidence
Kumamoto, JP · Author affiliation
Department of Neurology, National Hospital Organization Kumamoto Saishun Medical Center, Japan.Location evidence
Kitakyushu, JP · Author affiliation
Department of Neurology, Kitakyushu General Hospital, Japan.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Introduction Levodopa-carbidopa intestinal gel (LCIG) reduces the "off" time and improves the quality of life in people with Parkinson's disease (PwPD). However, real-world data from Asian populations, particularly Japan, are limited. Methods We retrospectively collected clinical data from PwPD who received LCIG across nine institutions in Kyushu, Japan. Patients who were assessed for key clinical parameters, including MDS-UPDRS Part III scores, Hoehn and Yahr (HY) stage, the daily "off" time, dyskinesia, and hallucinations, before LCIG initiation and at the latest available follow-up assessment at each participating institution were included in the study. The motor outcomes, daily "off" time, and neuropsychiatric complications were evaluated at baseline and at the latest available follow-up assessment. Statistical analyses were performed using the appropriate parametric and nonparametric tests. Results Thirty-seven PwPD were included based on the study criteria. LCIG therapy significantly reduced the MDS-UPDRS Part III scores (p=0.003) and HY stage during "off" states (p<0.001), as well as daily "off" time (p<0.001). No significant changes were observed during the "on" state. Compared with patients who continued LCIG, those who discontinued had significantly higher HY stages in the "on" state both before and after LCIG, and hallucinations were also significantly more frequent after LCIG initiation. Although no statistically significant differences were detected, PwPD who experienced tube-related complications were characterized by higher ages at disease onset and LCIG initiation and a greater HY stage during the "on" state following LCIG initiation. Conclusion This study provides region-specific real-world insights into LCIG therapy. Together with lessons from five instructive cases, these findings may help optimize LCIG management in clinical settings.